Eguia Vasco, Gonda Tamas Adam, Saif Muhammad Wasif
Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY 10032, USA.
JOP. 2012 Mar 10;13(2):131-4.
Despite treatment advances pancreatic cancer remains one of the most lethal malignancies. It is expected that early detection and screening of high risk patient population may have the most significant impact on altering overall survival in this disease. Serologic biomarkers may be the most useful in early detection and histology-based markers may have the most significant role in differentiating benign, pre-malignant and malignant lesions. Here we review several serum and tissue-based biomarkers and summarize new data presented at the 2012 ASCO Gastrointestinal Cancers Symposium (Abstracts #151, #164, #188) on the potential role of PAM4 in pancreatic cancer screening and diagnosis.
尽管治疗方法不断进步，但胰腺癌仍然是最致命的恶性肿瘤之一。预计对高危患者群体进行早期检测和筛查可能对改变这种疾病的总体生存率产生最显著的影响。血清生物标志物可能在早期检测中最有用，而基于组织学的标志物可能在区分良性、癌前和恶性病变方面发挥最重要的作用。在此，我们回顾几种基于血清和组织的生物标志物，并总结在2012年美国临床肿瘤学会（ASCO）胃肠道癌症研讨会上发表的关于PAM4在胰腺癌筛查和诊断中潜在作用的新数据（摘要#151、#164、#188）。
